SCHEMBL18213705

SCHEMBL18213705

C[C@@]12CCCC[C@H]1CC[C@@H]1C[C@]3(C)C(=O)CC[C@H]3C[C@H]12

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.58
HSD17B3 P37058 3/20 0.44
GPBAR1 Q8TDU6 4/20 0.40
LMNA P02545 3/20 0.40
CYP3A4 P08684 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SHBG P04278 2/20 0.40
SERPINA6 P08185 2/20 0.40
AKR1B10 O60218 2/20 0.40
AKR1B1 P15121 2/20 0.40
MAPK1 P28482 1/20 0.40
PMP22 Q01453 1/20 0.40
G6PD P11413 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
CYP2C19 P33261 1/20 0.40
OR51E2 Q9H255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16010063 0.83 CYP19A1 (0.59) CYP19A1GPBAR1CYP3A4MEN1KMT2A
SCHEMBL16020098 0.83 GPBAR1 (0.44) CYP19A1HSD17B3GPBAR1LMNACYP3A4
SCHEMBL16010607 0.82 GPBAR1 (0.62) HSD17B3GPBAR1LMNACYP3A4MEN1
SCHEMBL16009556 0.75 HSD17B3 (0.45) HSD17B3GPBAR1LMNACYP3A4MEN1
SCHEMBL1650324 0.73 CYP19A1 (1.00) CYP19A1HSD17B3GPBAR1LMNACYP3A4
SCHEMBL1908291 0.73 CYP19A1 (1.00) CYP19A1HSD17B3GPBAR1LMNACYP3A4
SCHEMBL17817126 0.73 CYP19A1 (1.00) CYP19A1HSD17B3GPBAR1LMNACYP3A4
SCHEMBL20714758 0.73 CYP19A1 (1.00) CYP19A1HSD17B3GPBAR1LMNACYP3A4
SCHEMBL12825203 0.73 CYP19A1 (1.00) CYP19A1HSD17B3GPBAR1LMNACYP3A4
SCHEMBL17341027 0.73 CYP19A1 (1.00) CYP19A1HSD17B3GPBAR1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160326127-A1 NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS WASHINGTON UNIVERSITY 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326127-A1 NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS GABRB3, GABRB1, GABRB2 CYP19A1 796/4885HSD17B3 533/4885GPBAR1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.